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26S proteasomeTheUbiquitin ProteasomeSystem(UPS)was discovered in two steps. Initially, APF-1 (ATP-dependent proteolytic
Factor 1) later identiﬁed as ubiquitin (Ub), a hitherto known protein of unknown function, was found to cova-
lentlymodify proteins. Thismodiﬁcation led to degradation of the tagged protein by – at that time – an unknown
protease. This was followed later by the identiﬁcation of the 26S proteasome complex which is composed of a
previously identiﬁed Multi Catalytic Protease (MCP) and an additional regulatory complex, as the protease that
degradesUb-tagged proteins.While Ub conjugation andproteasomal degradation are viewed as a continuedpro-
cess responsible for most of the regulated proteolysis in the cell, the two processes have also independent roles.
In parallel and in the years that followed, the hallmark signal that links the substrate to the proteasomewas iden-
tiﬁed as an internal Lys48-based polyUb chain. However, since these initial ﬁndings were described, our under-
standing of both ends of the process (i.e. Ub-conjugation to proteins, and their recognition and degradation),
have advanced signiﬁcantly. This enabled us to start bridging the ends of this continuous process which suffered
until lately from limited structural data regarding the 26S proteasomal architecture and the structure and diver-
sity of the Ub chains. These missing pieces are of great importance because the link between ubiquitination and
proteasomal processing is subject to numerous regulatory steps and are found to function improperly in several
pathologies. Recently, themolecular architecture of the 26S proteasomewas resolved in great detail, enabling us
to address mechanistic questions regarding the various molecular events that polyubiquitinated (polyUb) sub-
strates undergo during binding and processing by the 26S proteasome. In addition, advancement in analytical
and synthetic methods enables us to better understand the structure and diversity of the degradation signal.
The review summarizes these recent ﬁndings and addresses the extrapolated meanings in light of previous re-
ports. Finally, it addresses some of the still remaining questions to be solved in order to obtain a continuous
mechanistic view of the events that a substrate undergoes from its initial ubiquitination to proteasomal degrada-
tion. This article is part of a Special Issue entitled: Ubiquitin-Proteasome System. Guest Editors: Thomas Sommer
and Dieter H. Wolf.
© 2013 Elsevier B.V. All rights reserved.The diversity and complexity of the ubiquitin proteasomal
degradation signal
Ub, similar to many post-translational modiﬁers, mediates protein–
protein interactions. However, in contrast to many other types of mod-
iﬁcations it enables a complex and diverse array of biological processes.
As for proteasomal degradation, the prototypic ‘canonical’ signal is a
polyUb chain where the Ub moieties are linked to one another via an
isopeptide bond between the C-terminal Gly76 of the distal moiety
and internal Lys48 in the proximal one. The most proximal Ub moiety
is linked to an ε-NH2 group of an internal lysine (Lys) residue in the tar-
get substrate [1–3]. Furthermore, it was suggested that the shortest
chain recognized by the proteasome has to contain at least four Ubtin-Proteasome System. Guest
, Faculty of Medicine, Technion-
srael. Tel.: +972 4 829 5306;
ights reserved.moieties [4]. Recent investigations show however that the proteasomal
proteolytic signal is far more complex and diverse: chains based on dif-
ferent internal linkages, linear—head-to-tail chains,mixed chainsmade
of Ub-like (UbL) proteins and Ub, and surprisingly also a single Ub moi-
ety, can be recognized by the proteasome. Also, chains conjugated to in-
ternal residues other than Lys as well as to the N-terminal residue were
described, all challenging the current ‘canon’. All these different modiﬁ-
cations are depicted in Fig. 1.1. Single and multiple Ub moieties and structural characteristics of
the substrate can be parts of the proteolytic signal
Several recent investigations demonstrate that the proteasome can
recognize and degrade protein targets that were conjugated by a single
ormultiple single Ubs. One of the ﬁrst ﬁndings describedwas that a sin-
gle ubiquitination on a speciﬁc Lys residue on paired box 3 protein
(PAX3) – a regulator of muscle differentiation – targets the protein for
degradation [5]. The ubiquitination reaction is catalyzed by the TAF1
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signaling results in proteasomal degradation of the cell adhesion mem-
brane receptor Syndecan 4 (SCD4) that is involved in regulating cell mi-
gration during embryonic development [7].
Detailed mechanistic studies of monoubiquitination as a degrada-
tion signal revealed that Ub fused linearly to a peptide longer than 20
residues can efﬁciently target itself for degradationwith noneed for fur-
ther chain extension [8]. The hypothesis raised was that peptides
shorter than 20 residues that are fused to Ub cannot bridge the distance
between the bound Ub and the proteolytic chamber in the 20S sub-
complex – where the proteolytically active β-subunits are located –
and therefore cannot be degraded. Hence, only peptides longer than
20 residues can target the N-terminally fused Ub for degradation.
Since there is a minimal length of a peptide the degradation of which
can be driven by a single Ub moiety, the question raised was whether
there is a maximal length of a protein the degradation of which can be
driven by a single Ub moiety, and whether the length of a protein
plays a role in the extent of ubiquitination that leads to its degradation.
It was shown that a single Ubmoiety can support the degradation of ex-
tensions of up to ~150 residues [9]. Of note is that most of the exten-
sions used in these studies appeared to be artiﬁcial and raised the
concern that they are misfolded/denatured, and do not represent natu-
rally occurring proteins. However, a random and preliminary search for
cellular targets demonstrated that Cks2, a 79 residues cell cycle regula-
tor, and Hug1, a yeast protein involved in Mec1p-mediated checkpoint
pathway that responds to DNAdamage or replication arrest, are degrad-
ed both in a cell free system and in cells following monoubiquitination
[9]. Similarly, properly folded monoubiquitinated α-Synuclein, a 140
residue protein that was generated by a combination of chemical and
biologicalmethods,was degraded by a puriﬁed proteasome in amanner
that was completely dependent on the presence of the conjugated sin-
gle Ub moiety [9]. Furthermore, it was shown that that α-globin (142
residues) can be degraded following monoubiquitination [10,11].
The ﬁnding that Ub (that is a stably folded protein except for a short
C-terminal segment) is a long-lived protein, but a tail longer than 20
residues can target it for rapid degradation, strongly suggests that –
besides Ub– the proteasomal degradation signal has to contain a second
important characteristic, that of an unstructured tail or an initiation do-
main. This domain must be sufﬁciently long to cross the 19S sub-
complex and to reach the catalytic sites/proteolytic chamber in the β
rings, pulling the entire substrate behind it [12,13]. The questionwheth-
er this domain is part of the natural structure of the protein, a result of
misfolding, or generated by ubiquitination and/or 19S binding/process-
ing, is still elusive.
For other proteins, a more extended modiﬁcation by multiple single
Ubmoieties is necessary in order to promote their proteasomal degrada-
tion. For example, p105, the precursor of the NF-κB transcription factor
p50, undergoes multiubiquitinations in the C-terminal domain of the
precursor. These modiﬁcations result in processing of the precursor, re-
leasing theN-terminal p50 active subunit of the transcription factor [14].
The cell cycle regulator cyclin B1 is also degraded by the proteasome fol-
lowing multiubiquitination catalyzed by the APC/C E3 Ub ligase [15].
Restricting the number of Lys residues that serve as Ub anchors in the
case of p105 reduces the efﬁciency of processing whereas in the case
of cyclin B1 it “forces” the generation of oligo- and/or polyUb chain(s).
The above ﬁndings suggest a newdynamic concept for the Ub signal.
It seems that not all substrates require an equally long polyUb chains for
targeting them for proteasomal degradation, and that the proteolytic
signal can adapt itself to the substrate.Mechanistically, one can envision
that in the cell the ubiquitination and degradation machineries are
found in a loosely associated complex. As Ub moieties are added to
the substrate and the chain is elongated, the avidity of the conjugate
to the proteasome increases. Once the avidity reaches a certain thresh-
old, and a stable binding of the adduct to the proteasome is secured, it is
detached from the conjugating machinery, bound stably to the
proteasome, and degraded processively and efﬁciently. With largerprotein targets that may require a longer processing time, a longer
polyUb chain may be necessary to generate the required avidity. There-
fore, a single Ub moiety or a short chain is not sufﬁcient to bind stably a
long polypeptide for the proteasome to ascertain its processive diges-
tion. For substrates that aremultiubiquitinated, the spatial arrangement
of a large enough number of single Ub moieties that bind to multiple
points in the proteasomal Ub receptors ascertains the strong binding
necessary for processive degradation (see Section 7). In the case of cy-
clin B1, restriction of the number of Ub anchors that “forces” the forma-
tion of oligo-/polyUb chains, can substitute for the multiple single
moieties that were distributed among a higher number of anchors
along the protein substrate.
2. PolyUb chains
2.1. Homogenous Ub chains based on a single internal link
Ub has 76 residues with seven lysines in positions 6, 11, 27, 29, 33,
48 and 63. As noted, the most common Ub polymer involved in
targeting a substrate for degradationwas thought to be a homogeneous
chainwhere the Ubmoieties are linked to one another via an isopeptide
bond between the C-terminal Gly76 of the distal moiety and Lys48 of
the previously conjugated one [1]. Mass spectrometry analysis has
shown however that, in addition, chains based on Lys29, 11, 27 and 6
(in decreasing abundance) can also target proteins for proteasomal deg-
radation, and their formation is dependent on different stress states
[16]. Other studies have shown that homogeneous chains based on
Lys11, generated by the APC/Cyclosome Ub ligase, can also target cer-
tain proteins for degradation during cell division ([17–19] and reviewed
recently in [20]). These chains, like the ‘canonical’ Lys48-based chains,
appear also to bind to the Rpn10/S5a subunit of 19S sub-complex [21],
probably via a TEK box motif that is found on both the substrate and
the Ub moiety [22]. Other studies have shown that Lys33- [23,24] and
Lys63-based chains [25], are also recognized by the proteasome. It
should be noted that some of these results were obtained in studies
using cell free reconstituted systems. The validity of these systems
was questioned recently in a study showing that while puriﬁed
proteasome can degrade proteins conjugated with Lys63-based chains,
this does not occur in cells [26]. The reason being that in cells factors
such as ESCRT0 (Endosomal Sorting Complex Required for Transport)
and its components, STAM and Hrs bind to the Lys63 chains and inhibit
their association with the proteasome.
Thus, it appears that chains assembled via almost all Ub internal ly-
sines can target proteins for degradation by the proteasome. It will be
interesting to study the mechanistic and physiological conditions that
lead to the assembly of such chains on different protein substrates.
Some of the interesting questions are whether a single substrate can
be modiﬁed by several types of chains?, is the synthesis of these chains
catalyzed by a single or multiple ligases and under what conditions?,
and why at all single or different substrates require different chains
for their degradation?
2.2. Heterogeneous Ub chains based on different internal links
The fact that chains are synthesized enzymatically led naturally in
the assumption that theymust be homogenous, and all internal linkages
aremediated via a single speciﬁc Lys residue in theUbmoiety. However,
mass spectrometry analyses have shown that this is not the case, and
heterogeneous/mixed chains – where the linkages involve different in-
ternal lysines – are also recognized by the proteasome. One example is
cyclin B1 that, as noted, is targeted by multiubiquitinations [15], but
was also shown to be targeted by short Ub chains containing K11,
K48, and K63 internal linkages [27]. It is possible that in order to gener-
ate a proteasomal recognition signal of sufﬁcient Ub avidity, different
proteins use mixtures of chains of different lengths and internal
linkages. The generation of such chains may be dependent on the
Fig. 1. The variety of ubiquitin (Ub) and ubiquitin-like proteins (UbL) chains. A. The seven lysine residues in the Ubmolecule that serve as ubiquitination sites for additional distal moieties in
the polyUb chain. B. Homogenous chainswhere eachUbmoiety is bound to the previously conjugated one via the same lysine residue (exempliﬁed graphically for Lys48-based chain). C. A
free Ub chain (in this case, based on Lys63). D. HeterogeneousUb chainswhere eachUbmoiety can be linked to a different internal lysine residue in the previously conjugatedmoiety. The
heterogeneous chains can be either singly branched (E.; where each Ub moiety is conjugated by a single Ub) or multiply branched [F.; where each Ub moiety is conjugated by two (or
more) moieties, each on a different internal lysine residue]. G. Linear Ub chain where the Ub moieties are conjugated to one another head-to-tail (the C terminus of one Ub moiety is
bound in a linear peptide bond to the N terminus of the previous Ubmoiety). H. Modiﬁcation by a single Ubmoiety (monoubiquitination). I. Modiﬁcation by multiple single Ubmoieties
(multiubiquitination). J. Ubmodiﬁcation of ‘non-canonical’ internal residues (Ser, Cys, or Thr) in the target substrate. K. Ubmodiﬁcation of theN-terminal residue of the target substrate. L.
A single modiﬁcation or modiﬁcation by a chain of a UbL. M. Modiﬁcation by a mixed chain, the proximal part of which is made of a UbL whereas the distal one is made of Ub.
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hand, and on the ﬁtting of the chains to the appropriate receptors on
the proteasomal subunits on the other hand.
In addition,multiply branched (forked) chainswheremore than one
Ub moiety is conjugated to the previous moiety have also been de-
scribed [28,29]. However, these chains appear to associate only poorly
with the proteasome [29,30] and probably do not play a role in targeting
substrates for degradation. Thus, autoubiquitination of the E3 Ub ligase
Ring1B generatesmultiply branched chains on lysines 6, 27, and 48. The
role of these chains appears to stimulate the monoubiquitinating ligaseactivity of Ring1B towards its substrate – the nucleosomal histone H2A,
thus serving for self-regulation of the ligase [28].
2.3. Heterologous mixed Ub–UbL chains
Modiﬁcation of Lys residues of certain proteins by the UbL protein
Small Ub MOdiﬁer (SUMO) regulates a variety of processes, including
the cellular response to stress and DNA repair, signal transduction, and
targeting of proteins to their proper subcellular destinations [31–35].
SUMO is conjugated in most cases as a monomer to an internal Lys
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neous chain. The two modiﬁcations – SUMOylation and ubiquitination
– have been shown recently to cooperate with one another. Cells incu-
bated with the proteasome inhibitor MG132 were shown to accumulate
chains containing SUMO1 [36] and SUMO2 and 3 [37], which suggested
that these chains are involved in targeting their conjugated proteins for
proteasomal degradation. In a different experiment, puriﬁcation of Ub
conjugates yielded SUMO2 conjugates as well, suggesting that SUMO
can be part of a polyUb chain. Kinetic measurements suggested, though
did not demonstrate it directly, that SUMOylation is required for priming
subsequent polyubiquitination (and degradation), thus linking the two
modiﬁcations to the same pathway [37]. Heterologous chains composed
of both SUMO and Ub can lead to proteasomal degradation. Evidence
to this comes from studies on acute promyelocytic leukemia (APL)
that is treated with arsenic shown to induce the degradation of the
promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARα) fu-
sion protein (reviewed recently in Ref. [38]). Here, the protein ﬁrst un-
dergoes polySUMOylation that serves as a signal to recruit the RING
ﬁnger protein 4 (RNF 4) Ub ligase. The subsequent elongation of the
SUMO chain by Ub targets PML-RARα to proteasomal degradation
[39–41].
Interestingly, RNF4 that synthesizes Lys48-based chains on PML, can
synthesize Lys63-based chains during theDNA damage response. In this
case, polySUMOylated MDC1 (mediator of DNA damage checkpoint
1) recruits RNF4 which probably ubiquitinates the protein and/or
other proteins recruited to the damage point [42]. This ubiquitination
is important to secure proper recruitment of themany proteins involved
in the damage repair. Involvement of RNF4 in these two different
ubiquitination reactions are both dependent on prior SUMOylation
(reviewed in Ref. [43]). In another case it was demonstrated that dele-
tion of the speciﬁc deSUMOylating protease SENP1 results in suppres-
sion of the hypoxic response via targeting the Hypoxia Inducible
Factor (HIF)1α for rapid degradation [44]. It was shown that HIF1α is
SUMOylated which leads to the recruitment of the Ub ligase protein
von Hippel Lindau (pVHL), resulting in its ubiquitination and degrada-
tion (reviewed in Ref. [45]). Deletion of the SUMO protease most prob-
ably stabilizes the SUMO chain on HIF1α, which renders the elongation
of the chain by Ub and consequently HIF1α degradation more efﬁcient.
It is still not clear what stimulates SUMOylation of HIF1α in the ﬁrst
place, and how this modiﬁcation is related to normoxia where speciﬁc
proline residues in the protein are hydroxylated by proline hydroxylase,
a modiﬁcation that was also reported to recruit pVHL without pre-
SUMOylation requirement [46–48].
These examples unravel an additional layer of complexity of the Ub
system that broadens the signal beyond the Ub molecule. The coopera-
tion between the two modiﬁcation systems may contribute to a more
accurate control of protein degradation. One possibility is that proteins
are ﬁrst SUMOylated, and the modiﬁcation serves a non-proteolytic
function. They are then ubiquitinated and eliminated in order to
turn off the process that the SUMOylation initiated. We still do not
know how many protein targets are modiﬁed in this manner, and
whether this modiﬁcation occurs on proteins tagged by other UbLs be-
sides SUMO.
2.4. Linear Ub chains
In all the Ub chains described thus far, themoieties are linked to one
another via an angular isopeptide bond. Recently, another type of chain
was described where the moieties are linked to one another linearly —
head-to-tail. Here, the C-terminal Gly76 of the distal moiety is conjugat-
ed in a ‘classical’ linear peptide bond to the N-terminal residue of the
more proximal moiety. The linear chain is synthesized by the Ub ligase
Linear UB chain Assembly Complex (LUBAC) which is a complex made
of three proteins: (i) SHank-Associated Rh domain-interacting ProteIN
(SHARPIN); (ii) longer isoform of Heme-Oxidized Iron-regulatory pro-
tein 2 Ub Ligase-1 (HOIL-1L); and (iii) HOIL-1L-Interacting Protein(HOIP) [49–51]. While it has been shown that the linear chains are in-
volved in protein–protein interaction in the NF-κB activation pathway
(LUBAC polyubiquitinates NEMOwhich induces IKK activation and sub-
sequent degradation of IκBα; [52]), itwas demonstrated that LUBAC can
assemble linear Ub chains on GFP to which the ﬁrst Ub is fused (artiﬁ-
cially) to the N-terminal residue. This modiﬁcation led to proteasomal
degradation of the conjugated GFP, suggesting that linear Ub chains
can target substrates for degradation [53]. In another example, re-
searchers used the eukaryotic replication clamp PCNA, a natural target
of K63-linked polyUb chains, as a model substrate to compare the con-
sequences of modiﬁcation by different types of Ub chains. While the
K63-based chain-tagged PCNA was not degraded by the proteasome,
it was shown that a linear tetraUb chain is sufﬁcient to promote its
proteasomal degradation mediated by the Cdc48–Npl4–Ufd1 complex
without a requirement for additional modiﬁcation [54]. Though all the
experiments where linear Ub chains targeted the conjugated proteins
for degradation were carried out using artiﬁcial constructs in yeast
cells, they nevertheless demonstrate that the proteasome can recognize
these chains and degrade the tagged proteins.
3. Ubiquitination of residues other than Lys
3.1. Internal sites of ubiquitination
In most cases described, Ubmodiﬁes internal Lys residues of the tar-
get protein. Recent studies have shown however that Ub can be conju-
gated also via an ester bond to the hydroxyl group of Ser or Thr, or via a
thiol ester bond to the\SH group of Cys [55–59]. In some of these cases
however, the ubiquitination in a non-Lys residue was “forced” by
mutating all Lys residues on the target substrate, suggesting that
lysines are the preferred targets for Ub, but it can alsomodify other res-
idues. Thus, a lysineless cytosolic tail of MHC class 1 molecule was
ubiquitinated on a Cys residue by MIR1, a Kaposi's sarcoma-associated
herpes virus Ub ligase [55]. The ﬁnding that Lys residues are preferred
targets can stem from the fact that they aremore exposed on the surface
of the target proteins rather than from preferred chemical reaction con-
ditions. In another similar example, the mouse γ-herpes virus E3 ligase
mK3 alongwith the E2 Ube2j2 conjugated Ub preferentially to Thr and/
or Ser residues in the cytosolic tail of the MHC class I heavy chain. The
protein was then targeted via the Endoplasmic Reticulum Associated
Degradation (ERAD) pathway [60]. Interestingly, ubiquitination on ei-
ther the Ser or Thr residue was sufﬁcient to destabilize the protein. In
another case it has been shown that neurogenin (NGN), a transcription
factor that regulates neuronal differentiation, is tagged by Ub on Lys,
Cys, Ser, and Thr residues and also on its N-terminal residue. Thus, it ap-
pears that Ub chains can serve as proteasomal recognition signals re-
gardless of their anchoring sites [56,59].
3.2. Ubiquitination at the N-terminal residue
In addition to the modiﬁcation of internal residues, it appears that
Ub can modify also the α-NH2 group of the N-terminal residue of the
target protein.
The ﬁrst substrate that was identiﬁed as a target for N-terminal
ubiquitination was the myoblast determination protein 1 (MyoD) [61].
Several additional proteins that are similarly ubiquitinated were de-
scribed later [62–66]. An interesting case is that of SUMO. It was shown
that the E2Ube2W(Ubc16) can conjugateUb to its own amino terminus,
but also to that of SUMO in a manner dependent on the SUMO-targeted
Ub ligase (STUBL) RNF4. The N-terminal monoubiquitination of SUMO2
primes it for further polyubiquitination by the Ubc13/UEV1 E2, demon-
strating that N-terminal ubiquitination can regulate protein fate [67].
This is the ﬁrst description of an E2with N-terminal ubiquitinating activ-
ity which highlights the importance of E2s in directing the outcome
of E3-mediated ubiquitination [68]. N-terminal ubiquitination raises
an interesting hypothesis about another well-known and common
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to protect proteins from ubiquitination and subsequent destruction
[69–71].
The diversity of the amino acids that anchor Ub provides different
pKas and other chemical properties. This versatility probably provides
the UPS with additional layers of subtle recognition required for ﬁne
tuning of the proteolysis of its myriad substrates.
4. Are there consensus sites for ubiquitination?
Ub conjugation is catalyzed by a cascade of enzymatic reactions and
intuitively appears to be highly speciﬁc. Therefore and in contrast to
other post-translational modiﬁcations such as phosphorylation, it has
been surprising to ﬁnd that there is no consensus or homologous
ubiquitination site(s). It appears that for a fewproteins the ubiquitination
sites are unique, for some they share vague characteristics, whereas for
most others they appear to be promiscuous and can occur on different
Lys residues even if inserted in a non-natural position along the polypep-
tide chain, or even on non-Lys residues. This situation is opposed to
SUMOylation that occurs typically on Lys residues within the sequence
-ψ–K–X–E- [72].
For one group of proteins, p19INK4d, PAX3, ΙκΒα and p53, for exam-
ple, it appears that speciﬁc Lys residues that serve as Ub anchors have
been identiﬁed, though the neighboring residues do not share any com-
mon features among the different proteins. These Lys residues are either
single or multiple, and if multiple they appear to be clustered in one re-
gion of the target protein. However, the speciﬁcity of the lysines in the
cluster appears to be loose. This is because other lysines besides those
in the cluster can be involved too, and not all lysines in the cluster ap-
pear to be required, and their number and speciﬁc sites within the clus-
ter can vary. For example, in p19INK4d the major Ub acceptor is Lys62
[73] whereas in PAX3, modiﬁcation of either Lys437 or 475 is sufﬁcient
to target the protein for proteasomal degradation [6]. Interestingly,
ubiquitination on one Lys residue inhibits modiﬁcation of the other.
Modiﬁcation of ΙκΒα occurs on Lys21 and/or 22 [74], whereas for p53,
it is a cluster of 6 lysines in the C-terminal domain that was reported
to be modiﬁed [75].
Tandem mass spectrometry systematic analysis of yeast proteins
that enabled semi-quantitative and unbiased mapping of post-
translational modiﬁcation sites revealed that with one exception, all
ubiquitinated lysines must reside on the surface of the protein, and
even for the single case where the Lys residue is buried, ubiquitination
requires prior unfolding of the protein (K370 in glutamate dehydroge-
nase) [76–79]. There is also a preference for ubiquitination in loops
followed by α-helices [80]. Interestingly, both Ub lysines 48 and 63
that are modiﬁed most frequently in polyUb chains, reside within
loops. Similar ﬁndings were also reported in a different study where
the researchers demonstrated that preferred ubiquitination sites are
surface accessible Lys residues located in ordered secondary region
with the following priority: coil N helix N β-sheet N turn. Interestingly,
they also showed that these Lys residues are typically surrounded by
small positively charged residues [81].
In many cases, the ubiquitination sites are much more difﬁcult to
predict. In the case of the p105 precursor of NF-κB, ubiquitination occurs
on multiple lysines (~30) that reside in the C-terminal half of themole-
cule (~500 residue segment). This portion is degraded following (or
along with) processing of the molecule. However, the exact location of
the modiﬁed lysines and even their exact number does not seem to af-
fect the ultimate outcome [14,82]. For most substrates, it appears that
the ubiquitination sites are not speciﬁc, and for a few it was shown in
a clear way. Thus, Cyclin B1, for example, can be ubiquitinated on any
single Lys residue within the molecule, even if inserted in non-natural
sites [83]. Similar observations were reported also for the ζ chain of
the T cell antigen receptor [84].
The low evolutionary conservation and promiscuity of ubiquitination
sites probably attests to the vitality and adaptability of the UPS that oneof its most important roles is removal of foreign, mutated and otherwise
denatured/misfolded proteins. The “chemical” roots of this loose or
even lack of speciﬁcity reside in the high reactivity of the activated Ub
that can be attacked nucleophilically by different groups with various
characteristics.
5. Ubiquitin-independent proteasomal degradation
As a rule, the 26S proteasome recognizes only ubiquitinated pro-
teins. The single well-established and well-studied case where the
proteasome degrades a protein without prior ubiquitination is that of
Ornithine Decarboxylase (ODC). Interestingly however, the recognition
of ODC by the 26S proteasome ismediated by its “ownUb/chaperone” –
antizyme (Az) – which is a polyamine-induced protein. While the
degradation of ODC is clearly Ub-independent, the degradation of its
regulator Az, and of a speciﬁc antizyme-inhibitor (AzI) – an ODChomol-
ogous protein that regulates Az availability – are Ub-dependent
(Reviewed in Ref. [85]). Importantly, Ub-tagged substrates or even
free polyUb chains compete with AZ-stimulated proteasomal degrada-
tion of ODC, strongly suggesting that the two processes— AZ-ODC deg-
radation and degradation of ubiquitinated proteins, aremediated by the
same element(s) in the proteasome[86]. Interestingly, it was reported
that ODC is degraded also by the 20S proteasome, a process that is reg-
ulated by NAD(P)H quinone oxidoreductase 1 (NQO1) [85,87]. NQO1 is
a cytosolic enzyme that catalyzes the reduction of different quinones
using ﬂavin adenine dinucleotide (FAD) as a cofactor. It was shown to
rescue proteins containing intrinsically unstructured domains, such as
p53 and p73, from degradation by the 20S proteasome and to be regu-
lated – via mutually inhibitory loops – by the 20S proteasome [88].
Other researchers support the notion that an important role of the
20S proteasome is to degrade damaged proteins/proteins that are in-
trinsically disordered [89–91], though the discussion whether the 20S
proteasome has at all a role(s) in intracellular protein degradation has
not been settled yet.
An interesting discussion evolved around the degradation of p21, a
cyclin-dependent kinase (CDK) inhibitor, where it was suggested that
its regulated, cell cycle-dependent degradation is mediated by the 26S
proteasome in a process that requires prior ubiquitination, whereas its
unregulated, basal degradation is mediated by the 26S proteasome in
a process that does not require modiﬁcation by Ub [92].
6. Summary and outlook for the ubiquitin signal
As we can see, the Ub signal code is rather complex and its decoding
by current proteomic methods is difﬁcult if not impossible. That is be-
cause the analysis requires proteolytic destruction of the signaling
chain. Nevertheless, even in the absence of analytic tools, it is important
to attempt to understand the evolutionary reasons behind this com-
plexity. It appears that the myriad target substrates of the Ub system,
the need to set a ‘priority’ for their funneling into the proteasome, and
not less importantly, the numerous roles of non-proteolytic modiﬁca-
tions by Ub and UbL proteins, required the evolution of numerous dis-
tinct signals recognized by the proteasome, the shuttling proteins, and
other downstream effectors. The different structures and lengths of
theUb chains, and the various Ub-anchoring sites can provide the subtle
alterations to the strength and/or conformation of the interaction be-
tween the proteasome and the substrates, thus regulating degradation
rates. It should be noted that themost common chain targeting proteins
for degradation is based on Lys48 internal linkages, but even for those,
the ﬁnding that they contain also other linkages may provide them
with different characteristics required for ﬁne tuning of the proteolytic
process. Yet, it should be emphasized that the multiplicity of linkages
within a predominant Lys48-based chain can also reﬂect the promiscu-
ity/lack of accuracy of the conjugation machinery rather than any spe-
ciﬁc biological requirement/characteristic, and all that the proteasome
needs “to see” is a “critical mass” of a certain length of Ub moieties
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genesis of numerous diseases — certain malignancies, neurodegenera-
tive diseases, and immune and inﬂammatory disorders among them.
The added level of complexity of the signal is probably mirrored also
in these pathologies, and its understanding is necessary for future devel-
opment of novel therapeutic modalities to affect these aberrations.
7. Proteasomal recognition and processing of the proteolytic signal
7.1. Spatial organization of the 19S regulatory particle subunits
Targeting signals for ATP-dependent protease degradation is a fea-
ture that is well conserved in evolution, and the various proteases
share numerous characteristics. All protease complexes in this category
consist of a compartmentalized cylinder-shaped complex attached to an
AAA type ATPase that harbor an ‘unfoldase’ activity required for sub-
strate processing by the protease (for reviews see [93–97]). However,
unlike other ATP-dependent proteases, the 26S proteasome is the only
known Ub ATP-dependent protease. Subunit orientation and detailed
structure of the different subunits of the 20S catalytic particle was
resolved 15 years ago [98]. The 20S particle is barrel-shaped, composed
of four stacked heptagonal rings consisting of the two inner β catalytic
rings (β 1–7) and two outer α rings (α 1–7) of which β 1, 2, and 5 are
active subunits with distinct catalytic preferences. The outer α rings
serve as an interface for regulatory particle (RP) binding through a
pocket created between two adjacentα subunits. Upon RP engagement,
the α subunit N-termini that obstruct entry into the catalytic cavity
[98,99] are displaced and the entrance into the chamber's interior is di-
lated. One of the functions of the regulatory particle is therefore to open
the narrow entrance of the latent 20S catalytic particle (CP).
Recent studies have resolved the 19S particle structure at a sub-
atomic level [100–102]. The results have revised our view regarding
the RP architecture and require a revision of our model of how
polyubiquitinated substrates are recognized andprocessed by the 19SRP.
The initial view of the 19S suggested that it is composed of a sub-
complex proximal to the 20S catalytic particle termed ‘base’, and a distal
sub-complex termed ‘lid’ [103]. The base is composed of six ATPases —
Rpt1-6, Rpn1, Rpn2 and the two Ub receptors Rpn10/S5a and Rpn13.
The ‘lid’ contains the remaining Rpn subunits, of which only Rpn11
(PSMD14) has a known catalytic DUB activity [104,105]. In light of the
new structural information, the ‘base’ and ‘lid’ sub-complexes should
be viewed as assembly module intermediates, consistent with our cur-
rent view of proteasomal assembly mechanisms and kinetics [106].
The various structural data obtained from different sources
[100–102] combined with chemical cross-linking data to validate and
map proximal interactions [107,108], suggest the following scenario:
The hexameric Rpt ATPases are layered on top of the heptameric 20S
α subunit outer ring with a deﬁned tilt in respect to the coaxial plane
of the 20S catalytic particle. The ATPases are organized as a trimer of di-
mers in their assembly order [109], and are positioned towards the 20S
catalytic particle in a 6-fold rotational symmetry. For each RPT, the
ATPase domain is facing the α ring, whereas a second oligosaccharide
binding (OB) domain faces upwards. All the six OB domains are thus
generating an additional ring (see Fig. 2A). The AAA sub-domains ap-
pear to be arranged in a spiral staircase with Rpt3 and Rpt2 at the
highest and lowest positions in the ring, respectively, bridged by Rpt6
[100,102]. The three C-termini of Rpts 2, 3, and 5 are found docked to
the 20S α pockets [102]. This is consistent with the ﬁndings that Rpt2
and Rpt5 were able to activate the 20S with their C-termini [110,111],
and that Rpt3 and Rpt5 C-termini are essential for proteasomal assem-
bly [112]. In light of this arrangement, one can envision a substrate
moving through the ‘staircase’ generated by the ATPases encountering
the different conformational stages of the various ATPases in their vari-
ous nucleotide-bound states. The ﬁnal outcome of this transition is
unfolding of the substrate polypeptide chain allowing it to enter the
20S catalytic chamber. Structural information of the Rpt conformationduring the various nucleotide binding states will progress our under-
standing in respect to substrate unfolding and threading into the 20S
catalytic particle, and is therefore one of the future challenges waiting
ahead of us.
The two homologous and largest components of the regulatory
particle are Rpn1 and Rpn2 that are required for docking of various
proteasomal interacting proteins and Ub receptors [113–115]. Rpn2 lo-
calization was assigned to the far ends of the regulatory particle (in re-
spect to the 20S catalytic particle), whereas Rpn1 localization was
assigned to the sides of the regulatory particle [100]. In line with assem-
bly data [109,116], Rpn1 was observed to interact with Rpt1 and Rpt2,
whereas Rpn2 with Rpt3 and Rpt6 [100,101]. These surface-exposed lo-
cations of Rpn1 and Rpn2 would explain their ability to serve as plat-
forms for binding various proteasome adaptors, shuttling factors and
Ub receptors [113–115]. The structural data on the hexameric Rpts and
on Rpn1 and Rpn2 were obtained from either puriﬁed [100,101] or
in vitro assembled 26S particles [102]. These data differ from those
obtained using in vitro assembled hexameric Rpts–Rpn1–Rpn2 com-
plexes. Here, the Rpn1 and Rpn2were reported to form an inner stacked
channel embedded within the hexameric Rpt ring, where Rpn2 associ-
ates with the 20S catalytic particle [117]. This inner channel was sug-
gested to enable substrate entry into the catalytic particle [117]. These
discrepancies highlight the importance of structural data obtained from
intact complexes and change our view of looking at how substrates are
processed by the 26S proteasome (see below).
The remaining Rpn subunits – Rpn3, Rpn5, Rpn6, Rpn7, Rpn9 and
Rpn12 – all contain a proteasome–cyclosome initiation factor (PCI)
domain. They are found in a horseshoe scaffold structure with sole-
noid projecting away from the central horseshoe hub (Fig. 2B;
[100,101,108]). From the PCI structure it was clear that there is a direct
binding between Rpn5 and Rpn6 and the 20S α1 and α2 subunits. This
surprising ﬁnding was conﬁrmed by cross-linking experiments [102].
The PCI cluster extends all along the 19S RP, all the way from the cata-
lytic particle interface to the distal end of the RP, and adjacent to the
Rpt hexamer in the opposing side of the assigned Rpn1 [101]. This ﬁnd-
ing places for the ﬁrst time a ‘lid’ component (Rpn5 and Rpn6) with the
catalytic particle.
The remaining regulatory subunit assignments (with exception of
the proteasomal Ub receptors Rpn10/S5a and Rpn13) are the Mpr1,
Pad1 N-terminal (MPN) domain-containing metalloproteases Rpn8
and Rpn11. Based on the structural data obtained [100–102,108], the
catalytic inactive Rpn8 was suggested to form a dimer with the Rpn11,
a ﬁnding that would ﬁt well with the observed dimerization of soluble
Rpn8 [118] and the extensive cross-linking observed between the two
subunits [107]. A central density in the regulatory particle ﬂanked by
the PCI domain subunits on one side and Rpn2 on the opposing side
was assigned to the two MPN domain subunits, thereby positioning
Rpn11 in proximity to Rpt3, the highest ATPase in the RPT spiral stair-
case. This position ﬁts well with several cross-linking ﬁndings of
Rpn11with Rpt3 [108,119]. Rpn8 and Rpn11 probably undergo dynam-
ic movements during the ‘lid’ integration into the RP [102], possibly
explaining the activity of Rpn11 observed only in context of the assem-
bled 26S proteasome [104,105].
7.2. Polyubiquitin chain recognition by the 26S proteasome
The two well-characterized regulatory subunits that bind Ub are
Rpn10/S5a and Rpn13 [120,121]. The binding of Ub to Rpn10/S5a isme-
diated by two Ub-interacting motifs (UIMs), each forming an amphi-
pathic helix to create a low afﬁnity hydrophobic interaction with the
Ile44 centered hydrophobic patch of Ub [122,123]. Rpn13 mediates
proteasomal interaction with Ub through a Pleckstrin-like receptor for
Ub (PRU) domain that enables binding to the same hydrophobic surface
of Ub as Rpn10/S5a [114]. In addition to Ub, Ub-like (UBL) domain
also mediates polyUb substrate delivery to the proteasome via shuttle
factors that consist of UBL–UBA domains. These shuttles bind to
ARpt
hexamerAAA-ATPase
domain
OB
domain
B
PCI Rpn
subunits
Fig. 2.A. Subunit architecture of the hexameric Rpts (blue) assembled on top of the 20S particle (gray). Depicted are theAAA–ATPase andOBdomains of the hexameric Rpt ring. B. Subunit
architecture of the PCI-winged helix domain Rpn subunits (gold) resembles a horseshoe-shaped arrangementwith close proximity to the 20S particle. Structureswere generated based on
published data [102].
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UBA domain [124]. However, UBL-proteasomal interaction is not re-
stricted to the Rpn10/S5a and Rpn13 Ub receptors, [121,125] and is
alsomediated by Rpn1 [113,126]. Yet, exact location and high resolution
structure of the binding sites of the shuttle factors on the proteasome
are still missing. In addition to the above mentioned Ub/UBL binding
factors, cross-linking experiments identiﬁed Rpt5 in close proximity to
the proximal Ub moiety in a polyUb chain [127].
After assigning the densities of the various regulatory particle sub-
units, a small remaining density in the Rpn12–Rpn9 interface was
assigned to Rpn10/S5a [100–102,108] based on the crystal structure of
the Rpn10 VWA domain [128]. This assignment is consistent with the
Rpn10–Rpn12 observed interaction [128], and positions Rpn10 in
close proximity to Rpn8 [100], explaining the cross-linking of the two
subunits [107]. Rpn13 was observed to interact only with Rpn2
[102,108], consistent again with previous reports showing Rpn13
proteasomal docking via the Rpn2 subunit [129–131]. Similar to
Rpn11, proteasomal interaction of Rpn13 is necessary in order to enable
its Ub binding ability. Its binding to Rpn2 weakens an intra-molecular
association between the UCH37 and the Ub-binding domain within
Rpn13 [129], thereby ensuring that only proteasomal incorporated
Rpn13 will be able to bind Ub. In this respect it is worthy to note that
the additional Ub receptor Rpn10/S5a can bind Ub also as an isolated
subunit [132]. These observations are consistent with the suggested
role for the Rpn10/S5a receptor serving also as a proteasome-free shut-
tling factor carrying polyubiquitinated substrates to the proteasome
[132]. Furthermore, it was reported that Rpn10/S5a undergoes
multiubiquitination [133], which may also regulate non-proteasomal
association between the receptor and polyubiquitinated substrates. On
the other hand, Rpn13 is found only associated with the proteasome
[130] and therefore may not require any such regulation.
The subunit assignments on the 19S regulatory particle place the two
Ub receptors at a distance that varies between 70 and 100 Å [102,134],
a distance that sets a minimal length for the polyubiquitin chain
that is required in order to ascertain an avid binding between the
polyubiquitinated substrate and both Ub receptors (Fig. 3). In addition,
Rpn11 is positioned between the two Ub receptors, which is an ideal lo-
cation to ensure timely (rather than premature) deubiquitination, thus
committing the polyUb substrate for degradation [135].
NMR studies from in vitro assembled Rpn10/S5a, Rpn13 and Lys48-
linked diUb suggested a preferential binding of Rpn13 to the proximal
Ubmoiety [136]. Based on these and additional observations, itwas sug-
gested that Rpn13 and Rpn10/S5a can bind to a single K48 triUb chain
[136]. As a triUb chain cannot span the distance between Rpn10/S5a
and Rpn13, previous conclusions [136] obtained from structuresof individual subunits appear to be limited, and the in vivo scenario in
the intact 26S complex is probably different. Considering the open con-
formation of Lys48-based polyUb chains [137], the minimal length re-
quired for a polyUb chain to bind simultaneously to one Ub receptor
(Rpn13 or Rpn10/S5a) while being deubiquitinated by Rpn11, would
be four Ub [102]. This is consistent with previous reports regarding
the minimal lengths of four K48-based polyUb chains required in
order to support proteasomal degradation [4]. How theseﬁndings relate
to observations on the degradation of shorter Ub chains or even
monoubiquitinated proteins, or chains based on different internal link-
ages (see Section 2) remains to be elucidated.
The Ubp6/Usp14 sub-stoichiometric proteasomal DUBwas assigned
to the 26S particle by various maps using WT and ubp6Δ strains [102].
Its position was assigned to a variable location between the peripheral
Rpn1 and Rpn2 subunits in line with known data regarding Ubp6–
Rpn1 interaction [113,126,138] and also with Rpn1-independent inter-
actions [126]. The shuttling factors Rad23, Dsk10, and Ddi1 bind the
proteasome via Rpn1 [113,126,138]. This location places Ubp6 in close
proximity to Rpn1, and therefore also to polyubiquitinated substrates
that are brought by these shuttling factors. This proximity may enable
Ubp6 to process the polyUb chains on such substrates. The polyUb sub-
strates delivered to the proteasome by this mechanism may therefore
require an extended polyUb signal in order to bridge the longer distance
to Rpn11 and the hexameric Rpt ATPases.
The only proteasomal catalytic subunit absent from the yeast Sac-
charomyces cerevisiae is UCH37 (UCHL5). While no data regarding
UCH37 proteasomal positioning is available from the recently published
data, proteasomal binding of UCH37 was found to be Rpn13-dependent
[130,131], thus placing UCH37 in close proximity to substrates that are
bound to the proteasome via this Ub receptor. However, as the
Rpn13 Ub receptor is conserved between mammals and S. cerevisiae, it
is unlikely that the speciﬁcity of UCH37 is aimed towards Rpn13-
dependent polyubiquitinated substrates. This is also inferred from
the fact that UCH37 deﬁciency results in prenatal lethality in mice,
while Rpn13-deﬁcient mice survive to adulthood, suggesting Rpn13-
independent role(s) for UCH37 [139].
8. Pathologies associatedwith aberrations in recognition/processing
of the proteasomal degradation signal
Most of the pathologies described that are related to the Ub signal
stem from aberrations in the deubiquitinating enzymes. In most cases,
the mechanistic linkage between the phenotypic defect and the under-
lying biochemical defect has not been identiﬁed. Furthermore, even the
culprit ubiquitinated substrates involved in the pathogenesis of most of
Fig. 3. Intact 26S subunit architecture is presented, where the 20S particle is positioned
underneath the Rpt hexameric ring (blue). The Rpn11 DUB (green) is located on top of
the Rpt ring, positioned between the two Ub receptors Rpn10/S5a and Rpn13 (red). The
80 Å distance between the two Ub receptors is predicted to enable binding of a tetraUb
K48-linked polyUb chain. Structures were generated based on published data [102].
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normal processing involves a proteolytic substrate or a protein, the
ubiquitination of which serves a non-proteolytic function. We shall re-
view several pathologies involved in processing of the Ub signal, some
have been described only in model organisms.
The Ub C-terminal Hydrolase UCH-L1 (PGP 9.5) is an abundant brain
protein (comprising N1% of the total protein of the tissue), that is almost
absent from all other organs [140]. Members of a German family with
Parkinson's disease were identiﬁed as having missense mutation in
the UCH-L1 gene [141]. The mutation – Ile93Met – results in a partial
loss of the catalytic activity of this thiol protease, which could lead
to aberrations in the UPS, resulting in aggregation of proteins. Interest-
ingly, the enzyme was found in inclusion bodies immunostained for
ubiquitinated proteins which are characteristic to neurodegenerative
diseases [142]. A recent study implicates Aβ oligomers in impairing
BDNF retrograde trafﬁcking by down-regulating UCH-L1, relating
mechanistically a reduced activity of the enzyme to a defect observed
also in Alzheimer's Disease [143]. A simple hypothesis linking the
defective enzyme and the brain pathology is that an inactive or
haploinsufﬁcient enzyme will not release Ub from small molecules to
which it is conjugated via their amino, thiol, or hydroxyl groups, leading
to a deﬁciency in freeUb. Additionally, binding of the Ubmoiety of these
short adducts to the proteasome can inhibit the protease, leading to ac-
cumulation of other ubiquitinated proteins that are normally degraded
by the proteasome which can result in general impairment of the UPS.In mice, an inactivating mutation (intragenic deletion) of the homolo-
gous gene leads to gracile axonal dystrophy (GAD), an autosomal reces-
sive disorder that is presented as sensory ataxia at an early stage,
followed by motor ataxia later on. Pathologically, the syndrome is char-
acterized by a ‘dying-back’ type of axon degeneration and formation of
spheroid bodies in nerve terminals [144]. However, this simple model,
where the activity of an enzyme is related to a clear defect, was compli-
cated by a report that a polymorphic variation of serine to tyrosine at
codon 18 in the UCH-L1 gene is associated with a reduced risk of spo-
radic Parkinson's disease in certain populations [145]. As a matter of
fact, it was shown that the S18Y UCH-L1 polymorph, but not the WT
protein, protects dopaminergic nigral cells against MPTP toxicity,
suggesting that it has an antioxidant and neuroprotective effect [146].
Further complication came when the initial population genetics data
could not be conﬁrmed in later studies on other populations [147]. Cur-
rently, following numerous genetic, biochemical and neuropathological
studies, the association betweenUCH-L1, the dopaminergic system, and
the pathogenesis of Parkinson's disease, are still obscure.
Another defect that was described in the USP14 DUB (the mamma-
lian homolog of the yeast Ubp6; see below) is associated with synaptic
defects and aberration in neurotransmitter release [148]. The mice de-
velop severe tremors by 2–3 weeks of age, followed paralysis of the
hind limbs that leads to their death at 6–8 weeks of age. Detailed studies
revealed that the neuromuscular junctions are unable to mobilize a suf-
ﬁcient number of vesicles during times of intense activity to keep pace
with physiological rates of transmitter release. Importantly, unlike
UCH-L1 which is a soluble DUB, USP14 is a proteasome-associated
DUB, which probably relates the defect in a more direct manner to the
inability of the proteasome to degrade a target proteins, the accumula-
tion of which may underlie the pathogenesis.
Another interesting ﬁnding regarding Ubp6 is related to the control
of euploidy. Aneuploidy is associated with death and severe develop-
mental abnormalities in all organisms studied. It is the leading cause
of miscarriages and mental retardation in humans, is found in the vast
majority of human malignancies and may even support tumorigenesis.
The mechanisms that enable malignant cells to survive the adverse
effects of aneuploidy have yet to be unraveled. To understand the un-
derlying mechanisms that allow certain cells to survive aneuploidy,
Torres and colleagues [149] identiﬁed aneuploid yeast strains with im-
proved proliferative abilities. Their analysis revealed several mutations,
among them an inactivating mutation in the DUB Ubp6. The lack of the
enzyme was found to improve growth rate in aneuploid yeast strains,
probably by attenuating changes in cellular protein composition,
though the precise mechanism(s) have not been elucidated. It is clear
however that the effect of Ubp6 inactivation is not mediated via a deﬁ-
ciency in free Ub.
An additional defect relates to RPN11, the proteasomal integral DUB.
It confersmultidrug resistance to several chemotherapeutic agents such
as vinblastine, cisplatin, and doxorubicin [150]. It is not clear how
overexpression of a single stoichiometric subunit can affect the activity
of the entire proteasome. One hypothesis is that it can act also indepen-
dently, though the isolated subunit is not known to have catalytic activ-
ity [104,105].
Other defects are not related to signal processing and involve sub-
units of the proteasome and the signal itself. Ectopic expression of
RPN6 was found to confer protection from proteotoxic stress and to in-
crease lifespan in Canaerabditis elegans [151] which may suggest that
RPN6 is a candidate to correct age-related decreased proteasomal activ-
ity that may be involved in protein homeostasis disorders.
An interesting case is that of UBB+1, a Ubmolecule with an extend-
ed C-terminal tail of 19 residues. It is generated as a result of a frameshift
which is caused by dinucleotide deletions in GAGAG motifs in the re-
spective mRNAs of the coded proteins, and is thought to be the result
of ‘unfaithful’ transcription of the normal DNA by a mechanism called
“molecular misreading”. This pathological Ub was found in the brains
of early onset Alzheimer's Disease patients and also in brains of Down
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ronal cell death [153]. The possiblemechanismof the deleterious effects
of UBB+1was elucidated only recently. The protein cannot ubiquitinate
other targets but can be ubiquitinated. Being Ub by itself and having a
polyUb chain attached to it, results in its strong binding to the
proteasome. Yet, having a tail of 19 residues does not allow it to pene-
trate into the proteolytic chamber of the 20S proteasome (see
Section 1). The strong binding and its inability to be degraded make it
a strong proteasomal inhibitor [8]. Importantly, adding a single residue
to the 19 residue tail, alleviates the inhibition [8].
Last but not least, Ig secreting B lymphocytes are sensitive to
proteasomal inhibition. The reason being abnormal/misfolded Ig mole-
cules that would have otherwise been degraded by the proteasome via
the ERAD pathway, are accumulated in the ER following proteasomal
inhibition and induce apoptosis via the Unfolded Protein Response
(UPR) [154]. This observation served as the base for the development
of efﬁcient proteasome inhibitors (Velcade®/Bortezomib; Kyprolis®/
Carﬁzomib) that are being used successfully for the treatment of Multi-
ple Myeloma [155].
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